Drupal.behaviors.print = function(context) {window.print();window.close();}>
Terry Fox Institute, CPAC Provide $5M to Establish Validation Platform for Ovarian Cancer Biomarkers
October 21, 2011
Terry Fox Institute, CPAC Provide $5M to Establish Validation Platform for Ovarian Cancer Biomarkers
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Vermillion Posts 8 Percent Increase in OVA1 Sales, Announces Shift in Commercialization Strategy
May 17, 2013 / ProteoMonitor
Vermillion's OVA1 Sales Increase 8 Percent in Q1
May 16, 2013 / GenomeWeb Daily News
GenomeWeb Feature: The Unsteady March of Cancer Protein Biomarkers into the Clinic
May 10, 2013 / ProteoMonitor
Florida Licenses Provista Dx for Clinical Lab Services
May 7, 2013 / GenomeWeb Daily News
Vermillion Inks CRADA with Army to Evaluate OVA1
April 17, 2013 / GenomeWeb Daily News